CTOs on the Move

Capital Rx

www.cap-rx.com

 
Capital Rx is built around the mission of changing the way prescription drugs are priced and patients are serviced. A health technology company daring to reimagine the pharmacy benefits industry, Capital Rx is executing on that mission through its Clearinghouse Model® - the first ethical framework for drug pricing. Capital Rx`s enterprise pharmacy platform, JUDI™, connects every aspect of the pharmacy ecosystem in one platform, enabling patient engagement, and increasing efficiency to achieve the highest standards of clinical care.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.cap-rx.com
  • 228 Park Avenue South Suite 87234
    New York, NY USA 10003
  • Phone: 855.538.8897

Executives

Name Title Contact Details

Funding

Capital Rx raised $12M on 07/16/2019
Capital Rx raised $50M on 02/02/2021
Capital Rx raised $106M on 06/13/2022

Similar Companies

High View Manor

High View Manor is a Madawaska, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health and Medicine Policy Research Group

Health and Medicine Policy Research Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abbott Home Health Care Inc

Abbott Home Health Care Inc is a Stoughton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Archimedes, Inc.

Archimedes, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.